2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1605 IDH2 mutations confer venetoclax-dependent risk of treatment-emergent tumor lysis syndrome in newly diagnosed AML

Benjamin Frost, MD, Julia Keating, M.S.2, Dagam Jeong, PharmD3, Sean Lohle, BS4, Maysam Taktak, MS5, Evan C. Chen, MD6, Virginia O Volpe, MD7, Jacqueline S. Garcia, MD8, Eric Stephen Winer, MD9, Martha Wadleigh, MD10, Frederick D Tsai, MD, PhD11, Benson M. George, MD, PhD12, Rahul Vedula, MD13, Richard Stone, MD14, Daniel J DeAngelo, MD, PhD15, R. Coleman Lindsley, MD, PhD16, Marlise Rachael Luskin, MD, MSCE17, Shai Shimony, MD, MPH18
1 Brigham and Women's Hospital, Boston, MA, United States
2 Dana-Farber Cancer Institute, Boston, MA, United States
3 Dana-Farber Cancer Institute, Boston, MA, United States
4 Dana-Farber Cancer Institute, Boston, MA, United States
5 Dana-Farber Cancer Institute, Boston, MA, United States
6 Dana-Farber Cancer Institute, Boston, MA, United States
7 Dana-Farber Cancer Institute, Boston, MA, United States
8 Dana-Farber Cancer Institute, Boston, MA, United States
9 Dana-Farber Cancer Institute, Boston, MA, United States
10 Dana-Farber Cancer Institute, Boston, MA, United States
11 Dana-Farber Cancer Institute, Boston, MA, United States
12 Dana-Farber Cancer Institute, Boston, MA, United States
13 Dana-Farber Cancer Institute, Boston, MA, United States
14 Dana-Farber Cancer Institute, Boston, MA, United States
15 Dana-Farber Cancer Institute, Boston, MA, United States
16 Dana-Farber Cancer Institute, Boston, MA, United States
17 Dana-Farber Cancer Institute, Boston, MA, United States
18 Dana-Farber Cancer Institute, Boston, MA, United States

Introduction: Venetoclax (VEN) plus a hypomethylating agent (HMA) is standard therapy for patients (pts) with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. As VEN/HMA indications expand and FDA approval of an all-oral regimen simplifies outpatient use, identifying pts at risk for tumor lysis syndrome (TLS) with VEN/HMA, termed treatment-emergent TLS (teTLS), is increasingly important. Whether teTLS is determined by disease genotype has not been established. IDH2-mutant AML is sensitized to VEN, and we hypothesized that IDH2 mutations would confer VEN-dependent teTLS risk. We assessed genotype-specific teTLS risk during cycle 1 of VEN/HMA and compared rates by genotype to HMA alone in newly diagnosed (ND) AML.

Methods: We included pts ≥18 years with ND AML treated with VEN/HMA or HMA alone at our center between Sept. 2014 and Apr. 2025. Pathogenic mutations at diagnosis were detected by targeted DNA sequencing. Blast percentage (%) was the highest at diagnosis from the bone marrow aspirate or core biopsy, or, if no diagnostic marrow, the peripheral blood. TeTLS was defined as Cairo-Bishop laboratory TLS (Cairo, BJHaem 2004) from C1D1-D7. Among VEN/HMA pts, genes mutated in ≥10 pts that met a univariable threshold of p<0.10 were included in a multivariable logistic regression model for teTLS, along with pre-specified variables: baseline WBC, LDH, elevated Cr (>ULN), and blast %. We tested VEN-by-mutation interactions using Firth’s logistic regression; IDH2 was pre-specified, and other mutations were exploratory.

Results: 350 pts were included, of whom 287 (82%) received VEN/HMA and 63 (18%) received HMA alone. TeTLS occurred in 85 (24.3%) pts, with similar rates with VEN/HMA (24.0%) and HMA alone (25.4%, p=0.82) despite more frequent prophylactic allopurinol (p<0.001) and IV fluids (p=0.0012) with VEN/HMA. Clinical TLS occurred in 5.6% (16/287) of VEN/HMA-treated pts. Pts with teTLS had more VEN interruptions than those without (8.7% vs 2.3%; p=0.026).

Among VEN/HMA-treated pts (n=287), pts with teTLS had higher baseline blast % (median 79% vs 50%, p<0.001), WBC (7.7 vs 2.9 ×10⁹/L, p<0.001), LDH (371 vs 316 U/L, p=0.015), and rate of elevated Cr (20.3% vs 11.0%, p=0.047) than those without. Age (median 74 vs 73), sex, race, ELN 2024 risk, extramedullary disease, prophylactic allopurinol or IV fluids, VEN ramp-up, CYP3A inhibitor use, and HMA type were similar in pts with and without teTLS (all p>0.05). Pts with teTLS had lower potassium (median 3.9 vs 4.0, p=0.0013) and calcium (8.5 vs 8.7, p=0.043) than those without, but similar uric acid and phosphorus levels.

IDH2, CEBPA, NPM1, SRSF2, SF3B1, DNMT3A, and TP53 mutations met the univariable screening threshold; IDH1 mutations did not (OR 1.67; p=0.24). In the multivariable setting, IDH2 (OR 3.00, 95% CI 1.07-8.46; p=0.036) and CEBPA (OR 3.72, 95% CI 1.00-13.8; p=0.045) mutations were associated with higher teTLS risk, while DNMT3A mutations were associated with lower risk (OR 0.36, 95% CI 0.15-0.82; p=0.020). Blast % was the strongest covariate (OR 1.02 per 1% increase, 95% CI 1.01-1.03; p<0.001), and a data-derived cut-point of 70% blasts best separated pts with and without teTLS (AUC 0.66; sensitivity 0.64, specificity 0.67). No other univariable associations, including NPM1 (OR 2.23, 95% CI 1.10-4.43; p=0.023), persisted in the multivariable model. NPM1 mutations were associated with higher blast % (p<0.001).

IDH2 mutations remained associated with teTLS among DNMT3A-mutated pts (OR 5.16, 95% CI 1.22-20.9; p=0.027). Three of 12 CEBPA-mutated pts had in-frame bZIP mutations; teTLS occurred in 1/3 (33.3%) pts with bZIP mutations and 5/9 (55.6%) without. One pt had co-mutated CEBPA and DNMT3A.

The IDH2-associated teTLS risk was VEN-dependent (interaction p=0.0015). Among IDH2-mutated pts, teTLS occurred in 43.5% (10/23) with VEN/HMA and 0% (0/11) with HMA alone despite similar blast % (70% vs 81%, p=0.15). In contrast, CEBPA-associated teTLS risk was not VEN-dependent (interaction p=0.79).

Conclusion: As VEN/HMA use in AML expands, identifying pts at risk for teTLS is essential. Blast % at diagnosis was the strongest determinant of teTLS. The association between IDH2 mutations and higher teTLS risk was VEN-dependent but independent of AML burden, marking IDH2 as a unique, VEN-specific risk factor for teTLS. CEBPA mutations also conferred higher teTLS risk. Pts with IDH2 or CEBPA mutations may warrant closer monitoring at VEN/HMA initiation.

Benjamin Frost, MD: No relevant conflicts of interest to declare.